Quote | Terns Pharmaceuticals Inc. (NASDAQ:TERN)
Last: | $5.68 |
---|---|
Change Percent: | -6.12% |
Open: | $5.74 |
Close: | $6.05 |
High: | $5.96 |
Low: | $5.435 |
Volume: | 1,692,877 |
Last Trade Date Time: | 05/09/2024 03:00:00 am |
News | Terns Pharmaceuticals Inc. (NASDAQ:TERN)
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including on...
FOSTER CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including on...
Message Board Posts | Terns Pharmaceuticals Inc. (NASDAQ:TERN)
Subject | By | Source | When |
---|---|---|---|
June 25, 2007 | was thesauceman | investorshub | 06/25/2007 5:24:17 PM |
Still holding and waiting for that White Knight | followinsnsr | investorshub | 06/08/2007 12:10:56 AM |
Motorola to Acquire Terayon Communication Systems | midastouch017 | investorshub | 04/23/2007 1:04:01 PM |
Rumor has it that Motorola will announce the | realfast95 | investorshub | 04/22/2007 6:52:29 PM |
Perhaps in the next 3 weeks. DEF14A is | realfast95 | investorshub | 04/15/2007 12:01:54 AM |
News, Short Squeeze, Breakout and More Instantly...
Terns Pharmaceuticals Inc. Company Name:
TERN Stock Symbol:
NASDAQ Market:
FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including on...
FOSTER CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage bio...
FOSTER CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including on...